gx15-070ms

Metastatic Melanoma

Gemin XPhase 1/2Dormant

CC

40/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 29/ 100
Competitive Position: 73/ 100

Competitive context

104 Active assets in the Metastatic Melanoma cohort.

Asset / Sponsor	Phase	Rating
Cediranib M.D. Anderson Cancer Center	Phase 2	BBB
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Ifa Craig L Slingluff, Jr	Phase 2	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Therapeutic Autologous Lymphocytes Fred Hutchinson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

gx15-070ms is also rated in:

follicular lymphomaDormant

B

Indicative ·

57 / 100

small cell lung carcinomaDormant

CCC

Indicative ·

55 / 100

Hodgkins lymphomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.